Twelve‐month change in quantitative MRI calf muscle fat fraction in CMT1A predicts clinical change over 4 years
Annals of Clinical and Translational Neurology · 2025
DOI: 10.1002/acn3.52314 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Matthew R B Evans und 8 weiteren Autor:innen. Beteiligte Einrichtung: Queen Square Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Muscle, Skeletal, Adipose Tissue, Charcot-Marie-Tooth Disease. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.
Abstract (Originalsprache)
Objective
We measured clinical and quantitative MRI outcome measures in CMT1A to assess long‐term responsiveness, establish longitudinal validity and assess MRI as a bridging biomarker.
Methods
Twenty patients with CMT1A and 20 matched controls underwent MRI, myometry and clinical assessments up to four times over mean 4‐year follow‐up. Bilateral calf muscle MRI included T1‐weighted sequences with Mercuri grading and three‐point Dixon quantitative fat fraction assessment. Patients were grouped on baseline calf muscle fat fraction: normal 70%.
Results
Controls showed no significant change on MRI. CMT1A patients' calf muscle fat percentage progressed across all follow‐up visits: mean absolute change was +1.3 ± 1.2% (mean ± SD) at 12 months, +2.3 ± 2.2% at 27 months and 2.8 ± 2.9% at 49 months. Mercuri grades increased by 0.07 ± 0.11 per year. Responsiveness of individual muscle fat was less than for both calves combined. Patients with intermediate baseline calf muscle fat showed greater progression of 3.7 ± 2.3% at 27 months. There was strong correlation between rate of progression of calf muscle fat and CMT Examination Score ( ρ = 0.71, P = 0.005). Calf muscle fat progression at 12 months correlated significantly with annualised CMT Examination Score progression at final visit ( ρ = 0.65, P = 0.01).
Interpretation
We demonstrated a consistent progression of calf muscle MRI fat over 4 years, significant longitudinal correlation between CMT Examination Score and calf muscle fat, and potential as a bridging biomarker by 1 year change in fat correlating with long‐term clinical progression. Increasing study duration minimally increased responsiveness; however, selecting patients with intermediate fat fraction significantly increased responsiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Queen Square Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK.
- Department of Neuromuscular Diseases, Queen Square UCL Institute of Neurology, London, UK.
- Lysholm Department of Radiology, National Hospital for Neurology and Neurosurgery, London, UK.
- Neuroradiological Academic Unit, Queen Square UCL Institute of Neurology, London, UK.
ORCID-Profile: Jasper M Morrow
Förderung
- Medical Research Council
Zitieren
APA
Evans, M. R. B., Salhab, H. A., Sinclair, C. D. J., Shah, S., Hanna, M. G., Yousry, T. A., Thornton, J. S., Morrow, J. M., & Reilly, M. M. (2025). Twelve‐month change in quantitative MRI calf muscle fat fraction in CMT1A predicts clinical change over 4 years. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52314
Vancouver
Evans MRB, Salhab HA, Sinclair CDJ, Shah S, Hanna MG, Yousry TA, et al. Twelve‐month change in quantitative MRI calf muscle fat fraction in CMT1A predicts clinical change over 4 years. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.52314
BibTeX
@article{Evans2025,
author = {Evans, Matthew R B and Salhab, Hamza A and Sinclair, Christopher D J and Shah, Sachit and Hanna, Michael G and Yousry, Tarek A and Thornton, John S and Morrow, Jasper M and Reilly, Mary M},
title = {Twelve‐month change in quantitative MRI calf muscle fat fraction in CMT1A predicts clinical change over 4 years},
journal = {Annals of Clinical and Translational Neurology},
year = {2025},
doi = {10.1002/acn3.52314}
}
EUVIMED